Sunghee Yun (He/Him)

Co-Founder & CTO @ Erudio Bio, Inc., Co-Founder & CEO @ Erudio Bio Korea, Inc., Leader of Silicon Valley Privacy Preserving AI Forum (K-PAI), Director of AI Semiconductor @ K-BioX, AI-Korean Medicine Integration Initiative Task Force Member @ The Association of Korean Medicine, KFAS-Salzburg Global Leadership Initiative Fellow @ Salzburg Global Seminar, Visiting Professor @ Sogang University, Advisory Professor @ DGIST, Global Advisory Board Member @ Innovative Future Brain-Inspired Intelligence System Semiconductor of Sogang University, Network Expert @ Gerson Lehrman Group, Chief Business Development Officer @ WeStory.ai, and Advisor @ CryptoLab, Inc.

posted: 26-Nov-2025 & updated: 27-Nov-2025

Strategic Business Plan & Multi-Initiative Portfolio

Executive Summary

We propose to establish a Medical AI & Biotech Innovation Consortium that will launch multiple high-impact initiatives targeting the Life-Long Health Asset Management market—a multi-billion dollar opportunity emerging from the convergence of AI breakthroughs, aging populations, and the fundamental human need to maintain health throughout extended lifespans.

Rather than pursuing a single focused project, we will build a portfolio of synergistic initiatives spanning AI platform development, clinical applications, drug discovery, and health optimization services. This diversified approach:

  • De-risks the venture through multiple paths to market
  • Accelerates learning across complementary domains
  • Maximizes our team’s diverse capabilities
  • Positions Korea to lead multiple aspects of the medical AI revolution

The consortium uniquely leverages our team’s unparalleled combination of AI expertise, medical partnerships, industrial execution capability, and strategic networks spanning Silicon Valley, Korea, and global healthcare ecosystems.

I. The Opportunity - Why Now, Why Us

The Durable Market Truth

Humans have evolved to live 30-40 years, yet now routinely live 80+ years. This evolutionary mismatch creates permanent demand for solutions that optimize health throughout lifespans our biology was never designed to support. Unlike temporary market trends, this need is:

  • Universal every aging human faces this challenge
  • Inevitable cannot be solved through willpower or lifestyle alone
  • Urgent global populations aging rapidly (Korea leading this trend)
  • Permanent will persist as long as humans outlive their evolutionary design

The AI Inflection Point

For the first time, AI capabilities match biological complexity:

  • AlphaFold 3 earning the 2024 Nobel Prize validates AI’s transformation of life sciences
  • Multi-modal foundation models can now integrate genomic, proteomic, imaging, and clinical data
  • Agentic AI systems can coordinate complex research and clinical protocols
  • Privacy-preserving AI (homomorphic encryption) enables secure medical data utilization

Why Only We Can Execute This

Our team represents a once-in-a-generation convergence of capabilities:

Chanik Park — Execution power and customer relationships:

  • CCO at MangoBoost, direct experience commercializing cutting-edge technology
  • Former VP at Samsung Electronics with extensive enterprise sales experience
  • Deep understanding of technology adoption cycles in large organizations
  • Established relationships with potential enterprise customers
  • Proven ability to translate technical capability into business value

Sunghee Yun — World-class AI architect with proven track record:

  • PhD from Stanford under Stephen Boyd (Erdős number 3, mathematical genealogy to Gauss)
  • Led industrial AI at Samsung (12 years, tools still used by hundreds of engineers)
  • Senior Applied Scientist at Amazon ($200M+ revenue impact)
  • Co-Founder & CTO/CEO of Erudio Bio US/Erudio Bio Korea (Gates Foundation-backed AI biotech)
  • Leading K-PAI (Silicon Valley Privacy-Preserving AI Forum) with direct access to cutting-edge AI developments
  • Extensive academic network: delivered 70+ AI seminars at KAIST, SNU, POSTECH, Korea University, etc.
  • Deep theoretical foundation in convex optimization, the mathematical basis of modern AI

Don Kim — Unmatched US-Korea network bridge:

  • HR Head at SK hynix America, one of the world’s largest semiconductor companies
  • Deep relationships across Korean conglomerates (Samsung, SK, LG)
  • Direct access to Silicon Valley talent pools and investment communities
  • Experience navigating both Korean and American business cultures
  • Strategic HR expertise critical for building world-class research organizations

This combination—AI depth, network reach, and execution capability—does not exist in any other Korean team and rarely exists globally.

II. Strategic Vision - Life-Long Health Asset Management

The Paradigm Shift

Current healthcare is reactive: treat diseases after they appear. The future is proactive health asset management, analogous to financial planning but for the body’s most valuable asset.

Just as people plan finances from their 20s for retirement at 65, they should optimize health from youth for vitality at 80+. This requires a comprehensive ecosystem of technologies, services, and partnerships—not a single product.

The Portfolio Approach - Multiple Synergistic Initiatives

Rather than betting on a single approach, we will pursue 5 parallel initiatives that address different aspects of the health asset management opportunity:

Initiative 1 - Medical AI Foundation Model Platform (Technology Infrastructure)

  • Multi-modal AI model integrating genomic, proteomic, imaging, clinical, and lifestyle data
  • Core platform that powers other initiatives
  • Licensing/API revenue model

Initiative 2 - AI-Powered Clinical Decision Support Systems (B2B Healthcare)

  • Deployable tools for hospitals and clinics
  • Disease-specific applications (oncology, cardiology, neurology)
  • Immediate clinical utility and revenue

Initiative 3 - AI-Accelerated Drug Discovery & Biomarker Platform (Pharma Partnerships)

  • Novel therapeutic target identification
  • Biomarker discovery for early disease detection
  • Clinical trial optimization
  • Partnership revenue + royalties

Initiative 4 - Personal Health Optimization Service (B2C Consumer)

  • Continuous health monitoring and personalized recommendations
  • Integration with wearables and home diagnostics
  • Subscription-based premium wellness service

Initiative 5 - Medical AI Research Consortium (Ecosystem Building)

  • Regular expert gatherings (AI researchers, clinicians, data scientists, industry leaders)
  • Government engagement and policy influence
  • Talent pipeline and thought leadership

Each initiative has independent value but creates synergies with others. For example:

  • Foundation model (Initiative 1) powers clinical tools (Initiative 2) and drug discovery (Initiative 3)
  • Clinical partnerships (Initiative 2) provide data for foundation model (Initiative 1)
  • Consumer service (Initiative 4) provides real-world validation and additional data
  • Research consortium (Initiative 5) attracts talent and funding for all initiatives

This portfolio approach de-risks the overall venture while maximizing optionality and accelerating progress through cross-learning.

III. Detailed Initiative Breakdown

Initiative 1 - Medical AI Foundation Model Platform

Objective: Build Korea’s first comprehensive multi-modal medical AI foundation model

Technical Approach:

  • Integrate genomic, proteomic, imaging, clinical, and lifestyle data
  • Leverage privacy-preserving AI (homomorphic encryption) for secure data sharing
  • Train on Korean population data (genetic homogeneity = modeling advantage)
  • Create API/licensing platform for third-party developers

Timeline & Milestones:

  • Months 1-6: Data infrastructure setup, initial model training
  • Months 6-12: Clinical validation with partner hospitals
  • Months 12-24: Platform productization and API launch
  • Year 2+: International expansion and licensing

Revenue Model:

  • Platform licensing: ₩1-3B per major pharmaceutical/biotech company annually
  • API usage fees: Per-query pricing for third-party applications
  • Data licensing: De-identified datasets for research institutions

Initiative 2 - AI-Powered Clinical Decision Support Systems

Objective: Deploy immediately useful AI tools to hospitals for specific high-impact clinical scenarios

Focus Areas:

  • Cancer detection: Early identification from imaging + biomarker patterns (3-5 year lead time)
  • Cardiovascular risk: Personalized risk prediction and prevention strategies
  • Drug response prediction: Pharmacogenomic-based treatment optimization
  • Rare disease diagnosis: Pattern recognition across symptoms and test results

Clinical Partnerships:

  • Seoul Asan Medical Center (oncology focus)
  • Seoul National University Bundang Hospital (cardiology focus)
  • Samsung Medical Center (multi-specialty validation)
  • 2-3 additional regional hospitals

Timeline & Milestones:

  • Months 1-3: Partner hospital selection and MOU signing
  • Months 3-9: Pilot deployment in 3-5 hospitals
  • Months 9-18: Clinical validation studies and peer-reviewed publications
  • Months 18-36: National expansion to 50+ hospitals

Revenue Model:

  • Hospital licensing: ₩500M-1B per major hospital annually
  • Per-patient fees: ₩50K-100K per analyzed case
  • Outcome-based pricing: Share of cost savings from early detection

Initiative 3 - AI-Accelerated Drug Discovery & Biomarker Platform

Objective: Partner with pharmaceutical companies to accelerate drug development and discover novel biomarkers

Service Offerings:

  • Target identification: AI-powered discovery of novel therapeutic targets
  • Lead optimization: Molecular design for improved efficacy and safety
  • Biomarker discovery: Identify early disease markers for diagnostics
  • Clinical trial design: Patient stratification and outcome prediction
  • Repurposing analysis: Identify new indications for existing drugs

Partnership Strategy:

  • Tier 1: Major Korean pharma (Samsung Biologics, Celltrion, Hanmi)
  • Tier 2: Global pharmaceutical companies entering Korean market
  • Tier 3: Biotech startups needing AI capabilities

Timeline & Milestones:

  • Months 1-6: Partnership outreach and pilot project design
  • Months 6-18: 2-3 paid pilot projects with measurable outcomes
  • Months 18-36: Expand to 5-10 active pharmaceutical partnerships
  • Year 3+: Revenue-generating drug candidates and biomarker products

Revenue Model:

  • Upfront fees: ₩500M-2B per project for drug discovery services
  • Milestone payments: ₩1-5B at key development stages
  • Royalties: 2-5% on successfully commercialized drugs/diagnostics
  • Platform access: ₩1-2B annual subscription for ongoing partnerships

Initiative 4 - Personal Health Optimization Service

Objective: Create premium B2C service for proactive health management (future revenue driver)

Service Components:

  • Comprehensive assessment: Genetic testing, advanced biomarkers, imaging, lifestyle analysis
  • AI-powered insights: Personalized health trajectory predictions
  • Actionable recommendations: Nutrition, exercise, supplements, lifestyle modifications
  • Continuous monitoring: Integration with wearables, home diagnostics, regular check-ins
  • Expert consultations: Access to physicians, nutritionists, fitness coaches

Target Market:

  • Phase 1: High-net-worth individuals (₩5-10M annual spend on health)
  • Phase 2: Affluent professionals (₩1-3M annual wellness budget)
  • Phase 3: Corporate wellness programs (enterprise contracts)

Timeline & Milestones:

  • Months 12-18: Service design and beta testing with 50-100 pilot users
  • Months 18-30: Public launch and scaling to 1,000 users
  • Year 3-5: Scale to 50,000-100,000 users, add corporate wellness

Revenue Model:

  • Premium tier: ₩3-5M per person per year (comprehensive service)
  • Standard tier: ₩800K-1.5M per person per year (monitoring + recommendations)
  • Corporate wellness: ₩200K-500K per employee per year (volume pricing)

Initiative 5 - Medical AI Research Consortium & Ecosystem Building

Objective: Establish thought leadership, influence policy, and create talent pipeline

Activities:

  • Monthly expert forums: Regular gatherings of AI researchers, clinicians, data scientists, regulators
  • Annual conference: Major event attracting international speakers and participants (500+ attendees)
  • Policy working groups: Engage with government on AI healthcare regulation and standards
  • Academic partnerships: Joint research programs with universities (KAIST, SNU, POSTECH)
  • Talent programs: Internships, fellowships, research collaborations

Strategic Value:

  • Visibility: Position founders as thought leaders in medical AI
  • Recruitment: Pipeline for hiring top talent
  • Policy influence: Shape favorable regulatory environment
  • Partnerships: Network effect for clinical and commercial partnerships
  • Government funding: Enhanced credibility for grant applications

Timeline & Milestones:

  • Months 1-3: Launch with inaugural forum (50-100 experts)
  • Month 6: First government policy engagement
  • Month 12: First annual conference (300+ attendees)
  • Ongoing: Monthly forums, quarterly policy roundtables

IV. Execution Plan: From Vision to Reality

Immediate Actions (Months 1-3)

1. Consortium Formation & Governance

  • Formalize founding team structure, roles, and equity/ownership allocation
  • Establish legal entity (corporate structure vs. consortium model)
  • Define governance structure for multi-initiative coordination
  • Recruit 5-10 additional founding advisors across:
    • AI/ML research (KAIST, SNU, Stanford, MIT connections)
    • Clinical medicine (oncology, cardiology, neurology specialists)
    • Pharmaceutical industry (Samsung Biologics, Celltrion, global pharma)
    • Healthcare data science and regulatory affairs
    • Former government officials (MFDS, MOHW experience)

2. Initiative Prioritization & Phasing

  • Phase 1 Launch (Months 1-6): Focus on 3 initiatives
    • Initiative 2 (Clinical Tools): Fastest path to revenue and validation
    • Initiative 3 (Pharma Partnerships): High-value partnerships with clear ROI
    • Initiative 5 (Research Consortium): Ecosystem building and talent attraction
  • Phase 2 Development (Months 3-12): Infrastructure building
    • Initiative 1 (Foundation Model): Develop as backend for other initiatives
  • Phase 3 Launch (Months 12-24): Consumer market
    • Initiative 4 (Personal Health): Launch after clinical validation established

Technology Development Roadmap

Months 1-6: Foundation Model V1

  • Establish secure data infrastructure (homomorphic encryption for privacy)
  • Aggregate initial datasets from partner hospitals
  • Train initial foundation model on Korean population data
  • Validate on retrospective clinical outcomes

Months 6-12: Clinical Validation

  • Deploy pilot systems at 3-5 partner hospitals
  • Focus on high-impact use cases:
    • Early cancer detection from imaging + biomarkers
    • Cardiovascular risk prediction
    • Personalized treatment recommendations
  • Publish initial results in peer-reviewed medical journals

Months 12-24: Platform Expansion

  • Expand to 20+ hospitals across Korea
  • Add continuous monitoring capabilities (wearables integration)
  • Develop consumer-facing health optimization platform
  • Begin pharmaceutical partnerships for drug discovery applications

V. Competitive Advantages & Market Positioning

Why We Will Win Across Multiple Initiatives

1. Portfolio Synergies

  • Each initiative feeds the others: clinical data improves foundation model, which powers drug discovery
  • Shared infrastructure and talent pool reduces marginal cost of new initiatives
  • Multiple customer touchpoints create powerful network effects
  • Risk diversification ensures survival even if individual initiatives face setbacks

2. Unique Data Advantage

  • Korean population is relatively genetically homogeneous—easier to build accurate models
  • National health insurance system enables comprehensive data access
  • Privacy-preserving AI (homomorphic encryption expertise via CryptoLab connections) solves data sharing barriers
  • Multi-initiative approach generates diverse proprietary datasets

3. Clinical Integration Depth

  • Not just building AI models, but integrating into clinical workflows
  • Deep partnerships with top hospitals ensure real-world validation
  • Medical professionals as advisors prevent common AI healthcare failures
  • Multiple clinical use cases provide faster learning cycles

4. Technical Excellence

  • World-class AI team led by proven experts (Sunghee’s track record across Samsung, Amazon, biotech)
  • Access to latest Silicon Valley AI developments through K-PAI network
  • Mathematical rigor (convex optimization background) ensures robust, reliable models
  • Ability to execute across diverse technical domains (platform, applications, consumer products)

5. Execution Speed

  • Team has demonstrated ability to ship products, not just conduct research
  • Don’s network enables rapid corporate partnership formation
  • ChanIk’s sales expertise accelerates go-to-market across enterprise and consumer
  • Portfolio approach allows parallel execution rather than sequential dependencies

6. Strategic Positioning

  • Government AI priorities align perfectly with our mission
  • Strong relationships with potential government supporters enhance funding prospects
  • First-mover advantage across multiple medical AI domains in Korea
  • Ecosystem-building initiative (Initiative 5) creates moat through network effects

Competition Analysis by Initiative

Initiative 1 (Foundation Model):

  • International competitors: Google Health, Microsoft, Anthropic (focused on Western populations)
  • Our advantage: Korean population focus, privacy-preserving tech, clinical partnerships

Initiative 2 (Clinical Tools):

  • Competitors: Lunit, Vuno, other Korean AI healthtech startups
  • Our advantage: Broader platform, deeper clinical partnerships, portfolio synergies

Initiative 3 (Drug Discovery):

  • Competitors: BenevolentAI, Recursion, Insilico Medicine
  • Our advantage: Foundation model integration, Korean pharma relationships, faster market access

Initiative 4 (Consumer Health):

  • Competitors: InsideTracker, Function Health, GRAIL (limited in Korea)
  • Our advantage: Clinical validation, foundation model backend, local market knowledge

Initiative 5 (Ecosystem):

  • No direct competitors: Unique consortium-building approach
  • Advantage: First-mover in establishing Korean medical AI ecosystem

Overall Competitive Moat: Only team with combination of world-class AI, deep medical partnerships, pharmaceutical connections, and execution capability needed for comprehensive multi-initiative approach.

Conclusion

The convergence of AI breakthroughs, aging populations, and Korea’s strategic priorities creates a once-in-a-generation opportunity to build not just a company, but an entire ecosystem that positions Korea as the global leader in AI-powered health innovation.

Our multi-initiative portfolio approach provides multiple paths to success while creating synergies that no single-focus competitor can match:

  • Initiative 1 (Foundation Model) establishes technical leadership
  • Initiative 2 (Clinical Tools) generates immediate revenue and validates technology
  • Initiative 3 (Drug Discovery) creates high-value pharmaceutical partnerships
  • Initiative 4 (Consumer Health) builds massive long-term market
  • Initiative 5 (Research Consortium) attracts talent and influences policy

Each initiative has independent value. Together, they create an unassailable competitive moat.

Why This Team, Why Now

Our founding team uniquely combines:

  • World-class AI expertise with proven track record across Samsung, Amazon, and biotech
  • Unmatched US-Korea networks providing access to talent, capital, and partnerships
  • Execution capability demonstrated through successful technology commercialization
  • Strategic timing aligned with Korea’s national AI priorities and administration support

This combination—AI depth, network reach, execution power, and strategic positioning—does not exist in any other Korean team and rarely exists globally.

A Vision Beyond Business

While this plan focuses on execution and economics, the ultimate goal transcends commercial success. We are building solutions to one of humanity’s most important challenges: how to live healthily throughout lifespans our biology was never designed to support.

Success means:

  • Parents watching their grandchildren grow up with full cognitive vitality
  • Diseases detected years before symptoms, when they’re most treatable
  • Personalized health strategies that work for each individual’s unique biology
  • Korean medical innovations improving lives globally

This is the optimization problem worth solving—not just maximizing lifespan, but optimizing for human flourishing in all its dimensions.

This document represents a strategic overview of our multi-initiative portfolio. Detailed technical architecture, financial models, and go-to-market plans for each initiative available upon request. We welcome your feedback and look forward to discussing how we can work together to achieve this vision.